 |
 |
 |
Patients with neurodegenerative disorders have few therapeutic options. At Regenesance BV, we are developing therapeutic products that target the Complement system, part of the bodies innate immune system. Regenesance showed that in neurological disorders nerve regeneration is accelerated after inhibition of the Complement system. Regenesance BV believes this approach will offer treatment opportunities to patients suffering from acute or chronic neurological disorders. |
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutic Product PipelineRegenesance BV is building a pipeline of monoclonal antibodies and small molecules products to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway. Regenesance B.V. focuses on the development of treatments for chronic and acute neurological disorders such as Multiple Sclerosis and orphan indications such as ALS (Amyotrophic Lateral Sclerosis) and Myasthenia Gravis. |
About UsRegenesance BV was founded in November, 2009 on ground breaking research by its founder Prof Baas and his team from the Academic Medical Center (AMC) at the University of Amsterdam in the Netherlands. "Inhibition of Complement results in accelerated nerve regeneration in neurological disorders" . |
Latest NewsView latest press releases and publications below in pdf format. October 29 2012 | BIOCENTURY, emerging company profile (S. Hansen): Regenesance: Stopping the MAC attack. May 7, 2012 | Regenesance and ALS-TDI partner to investigate a potential treatment for ALS patients. January 25, 2012 | Nature Reviews Neuroscience , research highlights (S. Lewis), Neurodenerative disorders: Microglia get ready, set...
|
|||||||||
|
|
 |
|
|
|
|
|
|
|
Visit our Media Center page for more news. |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
|
|
 |
 |
||||||
 |
|